文献速递骨软组织肉瘤与黑色素瘤

FDG-PET/CT在3期黑色素瘤术后随访中的监测影像应用

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究评估3期黑色素瘤患者术后按亚期特异性方案行FDG-PET/CT监测的价值。假阳性率7%,6%发现可治疗的第二原发恶性肿瘤。亚期特异性PET监测的敏感性和特异性分别为70%和87%,复发患者中33例(52%)接受潜在根治性切除,10例(16%)在中位24个月后保持无病。

要点

  • 亚期特异性PET监测可无症状检出多数复发,阴性预测值高。
  • 复发患者中过半接受潜在根治性切除,部分获长期无病。
  • 假阳性率7%,需注意鉴别;6%检出可治疗第二原发肿瘤。

核心结论

  • 3期黑色素瘤术后按亚期特异性方案行FDG-PET/CT监测可无症状检出多数复发,阴性预测值高,并与复发时可切除、潜在可治愈病变的高检出率相关。

主要发现

  • 假阳性影像发现占7%,6%患者发现可治疗的第二(非黑色素瘤)恶性肿瘤。
  • 单次扫描的阳性预测值为56%–83%;阴性扫描对至下一次扫描前真无复发的阴性预测值为89%–96%。
  • 18个月时阴性PET对47个月(中位)随访期内任意时间真无复发的阴性预测值为80%–84%。
  • 亚期特异性PET监测总体方法的敏感性和特异性分别为70%和87%;复发患者中33例(52%)接受潜在根治性切除,10例(16%)在中位24个月后保持无病。

临床怎么用

  • 对3期黑色素瘤术后患者,可按亚期特异性复发概率制定FDG-PET/CT±脑MRI监测方案,以实现无症状复发的早期检出。
  • 监测中阴性PET结果具有较高阴性预测值,可用于患者 reassurance;阳性结果需结合临床鉴别假阳性。
  • 监测影像同时可能检出可治疗的第二原发恶性肿瘤,应予以关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As early detection of recurrent melanoma maximizes treatment options, patients usually undergo post-operative imaging surveillance, increasingly with FDG-PET/CT (PET). To assess this, we evaluated stage 3 melanoma patients who underwent prospectively applied and sub-stage-specific schedules of PET surveillance. PATIENTS AND METHODS: From 2009, patients with stage 3 melanoma routinely underwent PET +/- MRI brain scans via defined schedules based on sub-stage-specific relapse probabilities. Data were collected regarding patient characteristics and outcomes. Contingency analyses were carried out of imaging outcomes. RESULTS: One hundred and seventy patients (stage 3A: 34; 3B: 93; 3C: 43) underwent radiological surveillance. Relapses were identified in 65 (38%) patients, of which 45 (69%) were asymptomatic. False-positive imaging findings occurred in 7%, and 6% had treatable second (non-melanoma) malignancies. Positive predictive values (PPV) of individual scans were 56%-83%. Negative scans had predictive values of 89%-96% for true non-recurrence [negative predictive values (NPV)] until the next scan. A negative PET at 18 months had NPVs of 80%-84% for true non-recurrence at any time in the 47-month (median) follow-up period. Sensitivity and specificity of the overall approach of sub-stage-specific PET surveillance were 70% and 87%, respectively. Of relapsed patients, 33 (52%) underwent potentially curative resection and 10 (16%) remained disease-free after 24 months (median). CONCLUSIONS: Application of sub-stage-specific PET in stage 3 melanoma enables asymptomatic detection of most recurrences, has high NPVs that may provide patient reassurance, and is associated with a high rate of detection of resectable and potentially curable disease at relapse.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Lewin J, Sayers L, Kee D, et al. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol. 2018. PMID: 29659679. doi:10.1093/annonc/mdy124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。